Trial Profile
A Phase 3 Study to Evaluate the Efficacy and Safety of Dinaciclib or Ofatumumab in Subjects With Refractory Chronic Lymphocytic Leukemia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Dec 2022
Price :
$35
*
At a glance
- Drugs Dinaciclib (Primary) ; Ofatumumab
- Indications Chronic lymphocytic leukaemia
- Focus Registrational; Therapeutic Use
- Sponsors Merck Sharp & Dohme Corp.
- 07 Jun 2019 This trial has been completed in Finland , according to European Clinical Trials Database.
- 30 May 2019 This trial has been completed in Norway, according to European Clinical Trials Database.
- 26 Jan 2017 Results assessing safety and efficacy published in the Blood.